Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE
E. P. Mamounas*, M. Untch, M. S. Mano, C. S. Huang, C. E. Geyer, G. von Minckwitz, N. Wolmark, X. Pivot, S. Kuemmel, M. P. DiGiovanna, B. Kaufman, G. Kunz, A. K. Conlin, J. C. Alcedo, T. Kuehn, I. Wapnir, A. Fontana, J. Hackmann, J. Polikoff, M. SaghatchianA. Brufsky, Y. Yang, M. Zimovjanova, T. Boulet, H. Liu, D. Tesarowski, L. H. Lam, C. Song, M. Smitt, S. Loibl
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE'. Together they form a unique fingerprint.